CD8A and hepatocellular carcinoma: Accumulating evidence demonstrates that DC-based vaccines significantly enhance the proliferation and activation of CD8+ T lymphocytes while elevating serum interferon-gamma (IFN-γ) levels in patients with hepatocellular carcinoma (HCC), thereby contributing to improved overall survival (OS) (102).